Mozidat Olamide Bello,Mark Wadid,Aishwarya Malode et al.
Mozidat Olamide Bello et al.
In addition to traditional risk factors, patients with breast cancer are at an increased risk of atrial fibrillation due to cancer itself and certain cancer therapies. Atrial fibrillation in these patients adds to their morbidity and mortal...
Patient Characteristics and Real-World Treatment of Very Elderly Patients with Nonvalvular Atrial Fibrillation in Japan: An Administrative Claims Database Study [0.03%]
日本非瓣膜性房颤患者的真实世界治疗特征和患者特点：基于理赔数据库的研究
Ako Matsuo-Ohsawa,Jun Katada
Ako Matsuo-Ohsawa
Introduction: Very elderly patients with nonvalvular atrial fibrillation (NVAF) are at high risk for both ischemic and hemorrhagic events. This study aimed to understand the characteristics and real-world treatment of ver...
Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies [0.03%]
口服马昔腾坦治疗先天性心脏病所致肺动脉高压：来自OPUS/OrPHeUS研究的真实世界证据
Kelly M Chin,Richard Channick,Nick H Kim et al.
Kelly M Chin et al.
Introduction: Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) are scarce. The OPUS/OrPHeUS studies enrolled patients ...
ROsulord® sAfety for Patients with Dyslipidemia Study: A Non-interventional, Multicenter, Prospective, Observational Study in South Korea [0.03%]
ROsulord® 管理血脂异常患者的用药安全性研究：一项在韩国开展的非干预性、多中心、前瞻性观察研究
Do Young Kim,Sung Hea Kim,Eung-Ju Kim et al.
Do Young Kim et al.
Introduction: The ROsulord® sAfety for patients with Dyslipidemia study (ROAD study) in the Republic of Korea investigated the safety and efficacy of rosuvastatin in routine clinical practice. ...
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India [0.03%]
印度沙库必利/缬沙坦治疗高血压的专家意见
Uday M Jadhav,Saumitra Ray,T Govindan Unni et al.
Uday M Jadhav et al.
Hypertension, a key modifiable risk factor for cardiovascular diseases (CVD), significantly contributes to premature death and morbidity worldwide. Despite stabilization in age-adjusted global prevalence, the absolute number of hypertensive...
Predictors and Outcomes of Inappropriate Dosing of Direct Oral Anticoagulants in Patients Receiving Transcatheter Aortic Valve Implantation [0.03%]
经导管主动脉瓣植入术患者直接口服抗凝药不恰当用药的预测因素及预后研究
Danial Amoey,Mohamed Samy,Karim Elbasha et al.
Danial Amoey et al.
Introduction: Direct oral anticoagulant (DOAC) dose adjustment is based on age, renal function, and body weight. There is a paucity of data describing the factors associated with the prescription of inappropriate dosage a...
Sodium Zirconium Cyclosilicate for Renin-Angiotensin-Aldosterone System Inhibitor Optimization in Patients with Heart Failure with Reduced Ejection Fraction: A Retrospective Analysis [0.03%]
钠锆环硅酸锌用于心力衰竭合并肾素-血管紧张素-醛固酮系统抑制剂优化的回顾性分析
Rhys Williams,William Ford,Alexander James et al.
Rhys Williams et al.
Introduction: In this retrospective analysis, we evaluate the effectiveness of the potassium (K+) binder sodium zirconium cyclosilicate (SZC) in maintaining normokalemia and facilitating the initiation, optimization, and ...
Asia-Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study [0.03%]
东亚人群evolocumab使用现状、LDL-C降低情况及医患认知调查：HALES观察性研究结果
Hung-Fat Tse,Hung-Yu Chang,David Colquhoun et al.
Hung-Fat Tse et al.
Introduction: Real-world data are needed to understand the effectiveness of new therapeutic options for low-density lipoprotein cholesterol (LDL-C) reduction in Asia-Pacific clinical practice. Description of evolocumab us...
ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation [0.03%]
埃及心脏病专家共识关于血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在心血管结局的一级和二级预防中的应用：与CVREP基金会合作的2024年推荐意见
Mohamed Sobhy,Adel Eletriby,Hany Ragy et al.
Mohamed Sobhy et al.
Introduction: The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in regulating blood pressure (BP), with dysregulation of RAAS resulting in hypertension and potentially heart failure (HF), myocardial inf...
Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)' [0.03%]
关于《Tafamidis 61 mg的患者特征与依从性吗？基于德国法定健康保险数据（IQVIA™ LRx）的回顾性分析》来信
Arnt V Kristen,Carsten Tschöpe,Stephanie Schwarting et al.
Arnt V Kristen et al.